Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL D50 versus TIMOLIDE 10 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL D50 versus TIMOLIDE 10 25.
ALDORIL D50 vs TIMOLIDE 10-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Timolol is a non-selective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, reducing plasma volume and blood pressure.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
One tablet (timolol 10 mg / hydrochlorothiazide 25 mg) orally once daily. May be increased to two tablets once daily if needed.
None Documented
None Documented
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
The terminal elimination half-life of timolol is approximately 4 hours in patients with normal renal function, but may be prolonged to 12-20 hours in patients with renal impairment or hepatic dysfunction. The half-life of hydrochlorothiazide is 6-15 hours.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Timolol is primarily eliminated by renal excretion of unchanged drug and metabolites. Approximately 20% of a dose is excreted unchanged in urine, with the remainder as metabolites (mostly inactive). Fecal elimination accounts for less than 5%.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination